Maintenance Allergy Shots: Schedule, Dose, and Durability

Maintenance allergy shots are the SCIT injections delivered at the target maintenance dose during the multi-year phase of allergen immunotherapy that follows build-up. Per Cox L et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55 (DOI 10.1016/j.jaci.2010.09.034), maintenance means every 2–4 weeks for 3–5 years at approximately 0.5 mL of the maintenance concentrate. This is where the disease-modifying benefit accumulates — Durham SR et al., NEJM 1999;341:468–475 showed 3 years of maintenance produces 4 years of post-discontinuation remission. Maintenance is distinct from build-up (weekly dose escalation) and from symptomatic treatments (antihistamines, nasal steroids) that require ongoing daily use.

A brief 30-minute observation still follows every maintenance injection per Cox 2011 PP3 — it does not shorten just because a patient feels 'stable.' The rationale is that approximately 70% of fatal and systemic reactions to SCIT onset within the first 30 minutes, so traditionally the dose was given with trained staff and epinephrine available, as in the one-fatality-per-23.3-million-injection-visits safety record documented by Epstein TG et al. (PMID 23535092). Curex reproduces those safeguards at home: a prescribed epinephrine auto-injector is confirmed on hand before the first injection, your first dose and every dose change are supervised live over Zoom by the prescribing allergist, and you self-observe for the window after dosing — making safe at-home maintenance possible for eligible patients.

Cox 2011 PP3 specifies 3–5 years of maintenance as the typical course duration. The 3-year minimum is anchored by Durham SR et al., NEJM 1999;341:468–475, which showed 3 years of maintenance produced 4 years of post-discontinuation remission. Patients completing fewer than 2–3 years of maintenance typically experience relapse within 12–18 months of stopping. Some patients with more severe baseline disease or multiple sensitizations benefit from the full 5-year course. The decision to discontinue is clinical — based on symptom-medication scores, degree of improvement, and patient preference. No biomarker reliably predicts when it is safe to stop.

Missing the maintenance injection interval triggers a dose-reduction protocol per Cox 2011 PP3 interval-based dose-adjustment tables. The principle: the longer the gap beyond the scheduled 2–4-week interval, the larger the dose reduction required before returning to the target. A short overshoot of a few days may require no reduction; a gap of several weeks typically requires repeating a lower dose. Patients should notify their allergist before any known gap so that a reduced-dose vial can be prepared. Maintaining the scheduled interval is important for preserving the tolerogenic immune state established during build-up.

The maintenance dose per Cox 2011 PP3 is approximately 0.5 mL of the maintenance concentrate — the highest-concentration vial in the allergen extract series. In the ACAAI mixing guide color scheme, this is the red-cap 1:1 v/v vial. The target dose is established during build-up at the concentration and volume that produced clinical improvement without intolerable reactions. Patients should read the concentration on the vial label rather than relying on the color code — only 41% of US practices use the standard color-coding scheme per Prudenti 2023. The allergist will have prepared the maintenance concentrate as part of the multi-dose vial replaced every 6–12 months per CMS Article A57472.

The systemic-reaction rate during maintenance allergy shots is 0.1% per injection visit per Epstein TG et al., Ann Allergy Asthma Immunol 2013 (PMID 23535092) — the same baseline that applies across all phases of SCIT. Specific rates: 7.1 grade 1, 2.6 grade 2, and 0.4 grade 3 systemic reactions per 10,000 injection visits. One confirmed fatality occurred per 23.3 million injection visits during 2008–2012 across all phases. The WAO Systemic Reaction Grading System (Cox L et al., JACI 2010;125:569–574) classifies reactions from grade 1 (mild) to grade 5 (death). If throat tightness, breathing difficulty, generalized hives, or lightheadedness occur, use your prescribed epinephrine auto-injector immediately and call 911, then notify your care team — on a Zoom-supervised dose your allergist directs treatment live.

Build-up shots escalate the allergen extract dose weekly over 3–6 months, starting from the most dilute vial and progressing to the maintenance concentrate. Each build-up visit delivers a higher dose than the last. Maintenance shots deliver a constant dose — approximately 0.5 mL of the maintenance concentrate — at extended intervals (every 2–4 weeks) for 3–5 years. The build-up phase establishes tolerance; the maintenance phase sustains it and accumulates the durable benefit documented by Durham 1999 NEJM. The systemic-reaction risk is highest during build-up when doses are escalating; maintenance carries a stable but non-zero risk, which is why Curex keeps a prescribed epinephrine auto-injector on hand and supervises every dose-change shot live over Zoom while a brief observation still follows each dose at home.